Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Protective Efficacy of Recombinant Herpes Zoster Vaccine in Adults Aged 40 Years and Above
NCT07293065Phase 3Active, not recruiting
- Sponsor
- MAXVAX Biotechnology
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by MAXVAX Biotechnology. Started Dec 2025; status: active, not recruiting.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07293065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293065.